Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR

Similar Items

• Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
  od: Iskandar, Ireny Y.K., i dr.
  Izdano: (2018)
• A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis
  od: Yiu, Z.Z.N., i dr.
  Izdano: (2019)
• Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register
  od: Yiu, Zenas Z. N., i dr.
  Izdano: (2020)
• Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
  od: Yiu, Z.Z.N., i dr.
  Izdano: (2018)
• Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
  od: Yiu, Zenas Z.N., i dr.
  Izdano: (2018)